<h4>Objective</h4>Vunakizumab, a novel IL-17A inhibitor, has demonstrated satisfactory efficacy and safety for the treatment of moderate-to-severe plaque psoriasis. The gene discussed is IL17A; the disease is psoriasis vulgaris.